Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Nuformix Plc ( (GB:NFX) ) is now available.
Nuformix plc has announced its annual results, highlighting the progress of its lead program, NXP002, a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and other lung diseases. The company is seeking a business development partner to support the financial future of the group. NXP002, a novel form of tranilast, has shown promising preclinical results, demonstrating strong anti-inflammatory and anti-fibrotic effects. Nuformix is focused on securing orphan drug designation, maintaining intellectual property, and engaging in partnerships to advance NXP002’s development, which could significantly impact the treatment landscape for fibrosing lung diseases.
More about Nuformix Plc
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. They leverage their expertise to develop novel crystalline forms of existing drugs, aiming to create new commercial opportunities by improving drug properties and targeting new indications.
YTD Price Performance: 130.0%
Average Trading Volume: 42,677,136
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £887.1K
For an in-depth examination of NFX stock, go to TipRanks’ Stock Analysis page.
